DeanAnthonyLeeMDPhD
Pediatric Hematology & Oncology • Columbus, OHProfessor Director, Cell Therapy and Cancer Immunology Program
Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
555 S 18th St
Columbus, OH 43205Phone+1 614-722-2000Fax+1 614-355-2927
Summary
- https://www.nationwidechildrens.org/find-a-doctor/profiles/dean-a-lee
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2000 - 2003
Loma Linda University Health Education ConsortiumResidency, Pediatrics, 1996 - 1999
Loma Linda University School of MedicineClass of 1996
Certifications & Licensure
OH State Medical License 2016 - 2026
TX State Medical License 2003 - 2017
CA State Medical License 1998 - 2010
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) Start of enrollment: 2020 Jul 01
- Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Start of enrollment: 2018 Nov 01
Roles: Contact
- SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease Start of enrollment: 2021 Sep 20
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose
Molecular Therapy. Oncology. 2025-03-20 - Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma.Emily M Ringwalt, Mark A Currier, Andrea M Glaspell, Chun-Yu Chen, Matthew V Cannon
Molecular Therapy. Oncology. 2024-12-19 - Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma.Wen Luo, Aliza Gardenswartz, Hai Hoang, Yaya Chu, Meijuan Tian
Molecular Therapy. Oncology. 2024-12-19
Abstracts/Posters
- CD38 Knockout Primary NK Cells to Prevent Fratricide and Boost Daratumumab ActivityDean Anthony Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia CellsDean Anthony Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase ...Dean Anthony Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Novel Combo with Engineered NK Cells in Early Trial for Breast CancerJanuary 10th, 2025
Columbus Monthly’s 2020 Top Doctors: Columbus Research Giants Take on the VirusSeptember 1st, 2020
Nationwide Children's Hospital Explores a Possible Coronavirus TherapyMarch 14th, 2020
Grant Support
- MHC Restricted Immunotherapeutic Targets In AMLNational Cancer Institute2006
- MHC Restricted Immunotherapeutic Targets In AMLNational Cancer Institute2005–2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
